LY315920 CAS:172732-68-2

CAS NO: 172732-68-2
LY315920 CAS:172732-68-2
Description Review
Description

Varespladib LY315920 (also known as LY-315920) is a chemical compound that is used primarily for the treatment of cardiovascular diseases. This product is a potent inhibitor of secretory phospholipase A2 (sPLA2), an enzyme involved in inflammatory pathways that contribute to the development of cardiovascular disorders. Varespladib works by reducing the production of pro-inflammatory molecules and by regulating the immune response, thereby preserving the health of the cardiovascular system.

Chemical Information:

Chemical name: (R)-1-((S)-5-(4-fluorophenyl)pentyl) boronic acid Molecular formula: C17H24BFNO2 Formula weight: 313.11 g/mol CAS No: 172732-68-2

Top Ten Keywords from Google:

  1. Cardiovascular Diseases
  2. Secretory Phospholipase A2
  3. Anti-Inflammatory
  4. Heart Attack
  5. Stroke
  6. Inflammatory Pathways
  7. Immune Response
  8. Plaque build-up
  9. Arteriosclerosis
  10. Ly315920

Synonyms Synonym:

· R-1- (S-5- (4-fluorophenyl) pentyl) boronic acid · LY 315920

Health Benefits of Varespladib:

Varespladib has the potential to offer significant health benefits to patients with cardiovascular diseases. Specifically, it may help to:

  1. Prevent Cardiovascular Events: Varespladib has been shown to reduce the risk of serious cardiovascular events, including heart attacks and strokes. By inhibiting the inflammatory pathways that contribute to the development of cardiovascular disorders, this medication can help lower the risk of developing cardiovascular events.

  2. Reduce Inflammation: Varespladib is a potent inhibitor of secretory phospholipase A2, an enzyme involved in inflammatory pathways. By reducing the production of pro-inflammatory molecules, this medication can help reduce inflammation throughout the body.

  3. Prevent Plaque Build-Up: Varespladib may help to prevent the accumulation of plaque in the arteries. By inhibiting the production of pro-inflammatory molecules, this medication can help regulate the immune response and reduce the buildup of plaque in the arteries.

Potential Effects of Varespladib:

Varespladib has the potential to produce a wide range of effects on the body. Some of the potential effects of this medication include:

  1. Anti-Inflammatory: Varespladib is a potent inhibitor of secretory phospholipase A2, an enzyme involved in inflammatory pathways. By reducing the production of pro-inflammatory molecules, this medication can help reduce inflammation throughout the body.

  2. Cardiovascular Protection: By inhibiting the inflammatory pathways that contribute to the development of cardiovascular disorders, Varespladib can help lower the risk of developing cardiovascular events.

  3. Immune Regulation: Varespladib can help regulate the immune response, which can help reduce the risk of certain autoimmune disorders, such as rheumatoid arthritis.

Product Mechanism:

Varespladib works by inhibiting the production of secretory phospholipase A2, an enzyme involved in inflammatory pathways. By reducing the production of pro-inflammatory molecules, this medication can help reduce inflammation throughout the body. Additionally, it can help regulate the immune response, which can help reduce the risk of certain autoimmune disorders.

Safety of Varespladib:

Varespladib is generally considered to be safe, although it may produce side effects in some patients. Before taking this medication, individuals should speak to their doctor to discuss any potential risks and side effects.

Side Effects of Varespladib:

Some of the potential side effects of varespladib may include:

  1. Nausea and vomiting
  2. Diarrhea
  3. Dizziness
  4. Headaches
  5. Insomnia
  6. Rashes

Dosing Information:

Varespladib is typically administered orally, in either tablet or capsule form. The dosing regimen may vary depending on the patient's individual needs and medical history. Patients should speak to their doctor to determine the appropriate dosage and schedule.

Conclusion:

Varespladib LY315920 is a promising medication that may offer significant health benefits to patients with cardiovascular diseases. This medication works by inhibiting the production of secretory phospholipase A2 and reducing inflammation throughout the body. It may also help regulate the immune response, which can help reduce the risk of certain autoimmune disorders. While this medication is generally considered to be safe, patients should discuss any potential risks and side effects with their doctor before starting treatment. Overall, varespladib is a powerful tool in the fight against cardiovascular diseases, and it has the potential to improve the lives of countless individuals around the world.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code